UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1, 2011

VENTRUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-8729264
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer ID Number)
787 7th Avenue, 48th Floor, New York, New York	10019	
(Address of principal executive offices)	(Zip Code)	

Registrant's telephone number, including area code (212) 554-4300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On February 1, 2011, Ventrus Biosciences, Inc., issued a press release announcing the completion of its clinical development staffing. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated February 1, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VENTRUS BIOSCIENCES, INC.

Date: February 1, 2011

By: /s/ David J. Barrett
David J. Barrett, Chief Financial Officer

EXHIBIT 99.1

Ventrus Completes Clinical Development Staffing

NEW YORK, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing.

Ventrus has contracted Mohan Kabadi, Ph.D. as head of Pharmaceutical Product Development and Manufacturing. Dr. Kabadi will be responsible for the supply of commercial grade API and drug product for our products and for the development of the extended release forms of Diltiazem cream. Previously, Dr. Kabadi was at Bristol-Myers Squibb, Novartis, Pfizer, Faulding, and Roche. In the past 20 years, Dr. Kabadi has formulated, manufactured and successfully launched more than 25 ethical, generic, and specialty products. Currently, he serves as the President of American Association of Indian Pharmaceutical Scientists (AAiPS) and holds membership as well as active participation in AAPS and CRS.

Monil Shah has been employed as Vice President, Clinical Research and Development. Dr. Shah has a Doctorate in Pharmacy from Rutgers University and drug development experience from Novartis, Amgen, Fibrogen, and most recently was Director of Clinical Strategic Planning at Celgene.

Celina Scholl has been employed as Clinical Project Manager. Ms. Scholl has drug development experience from Novartis and Merck Pharmaceuticals and most recently with GSK Biologics.

Christina S. DiArcangelo, CEO of Armonia Clinical Research, has been contracted to manage our outsourcing activities. Ms. DiArcangelo's expertise includes global outsourcing, project management, global contracting, site contracting, process development, and site and service provider budget development and negotiations.

John Dietrich, formerly vice president of clinical operations of Ventrus and currently consulting with Ventrus, will continue consulting with Ventrus, and will manage our toxicology program and support our publication activities. Dr. Dietrich received his Ph.D. in Pharmacology and has been in the biopharmaceutical industry since 1979. Dr. Dietrich has held senior management positions in drug research and development for a number of biotech companies.

CEO Russell Ellison commented on the completion of Ventrus clinical development team: "We are very pleased to now be fully staffed with such a qualified and experienced drug development team to help us optimally progress our exciting product portfolio."

About Ventrus

Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Our lead product, Iferanserin (VEN 309) is a new chemical entity, or NCE, for the topical treatment of hemorrhoids, which targets a specific serotonin receptor (5HT2A) thought to be important in the disease. The first late phase clinical trial (Phase III) with Iferanserin is expected to start mid-year 2011 and we expect data to be available in the first quarter of 2012

Our additional product candidate portfolio consists of two in-licensed late-stage drugs intended to treat anal fissures (VEN 307) and fecal incontinence (VEN 308). The first Phase III clinical trial with Ven 307 has begun in Europe and we expect data to be available in the second quarter of 2012. These candidates are two molecules that were previously approved and marketed for other indications and that have been formulated into our proprietary topical treatments for these new gastrointestinal indications.

Please Note: The information provided herein contains estimates and other forward–looking statements regarding future events. Such statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: our ability to retain and hire necessary employees and to staff our operations appropriately; the unpredictability of the clinical development of our product candidates and of the duration and results of regulatory review of those candidates by the FDA and foreign regulatory authorities; the cost, timing and results of clinical trials and other development activities involving our product candidates; our anticipated capital expenditures and our estimates regarding our capital requirements; and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

CONTACT: ●Ventrus Biosciences, Inc.● David Barrett● 212-554-4506 ●dbarrett@ventrusbio.com